07.25.12
Coldstream Laboratories is expanding its manufacturing facility, enhancing a number of key systems at its sterile drug product manufacturing plant aimed at improving efficiencies and expanding capacity to produce parenteral products. The company is also expanding lyophilization capacity to extend the range of solvents that can safely be handled. The upgrades will be completed in August 2012.
Dr. Vickie Hall, vice president of operations, said, “The demand for our services has grown markedly over the last year. We are expanding our capacity to generate sterile water for injection and other systems to keep pace with demand.”
“The market is signaling that the ability to handle organic solvents in our lyophilizers is an important differentiator for Coldstream,” said Eric Smart, executive vice president. “We have helped a number of clients overcome solubility and stability challenges in the development of practical manufacturing processes by employing organic solvents. While our lyophilization equipment was already capable of handling many organic solvents, these additional features will expand the number of solvents we can handle safely to help our clients overcome challenges in product development.”
Dr. Vickie Hall, vice president of operations, said, “The demand for our services has grown markedly over the last year. We are expanding our capacity to generate sterile water for injection and other systems to keep pace with demand.”
“The market is signaling that the ability to handle organic solvents in our lyophilizers is an important differentiator for Coldstream,” said Eric Smart, executive vice president. “We have helped a number of clients overcome solubility and stability challenges in the development of practical manufacturing processes by employing organic solvents. While our lyophilization equipment was already capable of handling many organic solvents, these additional features will expand the number of solvents we can handle safely to help our clients overcome challenges in product development.”